article thumbnail

New SNMMI President Cathy Cutler, PhD Discusses Current Challenges and Goals for Nuclear Medicine

Diagnostic Imaging

shared her perspective on a number of topics affecting nuclear medicine, ranging from isotope availability and reimbursement challenges for diagnostic radiopharmaceuticals to increasing patient interest in PET imaging. In a recent interview, Cathy Cutler, Ph.D.,

article thumbnail

Illuminating the Future: Recent Breakthroughs in Nuclear Medicine Advancements (Maharashtra, Raigarh, Sangli, Satara, Sindhudurg, Solapur, Thane, Wardha, Washim, Yavatmal)

Future Teleradiology

Teleradiology-India Introduction: Nuclear medicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclear medicine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Carolyn J. Anderson, PhD, Receives SNMMI 2024 Georg Charles de Hevesy Nuclear Pioneer Award

Imaging Technology

Anderson , PhD, a trailblazer in nuclear medicine, has been named the 2024 recipient of the Georg Charles de Hevesy Nuclear Pioneer Award. The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto.

article thumbnail

A Closer Look at Urinary Activity and PET Radiopharmaceuticals for Prostate Cancer Imaging

Diagnostic Imaging

In a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference in Chicago, Phillip Kuo, M.D.,

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.

article thumbnail

Martin B. Shirley Executive Vice President Sales, Marketing & Clinical Operations

TTG Imaging Solutions

Martin Shirley was appointed the role of TTG Imaging Solutions Executive Vice President Sales, Marketing & Clinical Operations in April of 2023 as part of TTG Imaging Solutions acquisition of Digirad Health, Inc and its subsidiaries Digirad Diagnostic Imaging, Inc and Digirad Imaging Solution, Inc.